More articles from Commentary

  • The underappreciated role of documentation in improving COPD care
    Solmaz Ehteshami-Afshar, MD, MSc and Naseema Merchant, MD
    Cleveland Clinic Journal of Medicine May 2022, 89 (5) 249-251; DOI: https://doi.org/10.3949/ccjm.89a.21044

    Despite the importance of providing guideline-concordant care, there are still barriers to implementing evidence-based recommendations in providing care for patients with chronic obstructive pulmonary disease.

  • Peyronie disease and erectile dysfunction: A potential new paradigm
    Drogo K. Montague, MD
    Cleveland Clinic Journal of Medicine December 2021, 88 (12) 661-663; DOI: https://doi.org/10.3949/ccjm.88a.21027

    Viewing Peyronie disease as related to erectile dysfunction allows for the possibility of preventing the disease in patients with erectile insufficiency.

  • SGLT-2 inhibitors in heart failure: Time for broader eligibility and earlier initiation
    Enrico G. Ferro, MD, Bertram Pitt, MD and Deepak L. Bhatt, MD, MPH
    Cleveland Clinic Journal of Medicine November 2021, 88 (11) 601-606; DOI: https://doi.org/10.3949/ccjm.88a.21045

    SGLT-2 inhibitors remain vastly underused in clinical practice despite their broad cardiorenal benefits.

  • Another influenza season in the shadow of the COVID-19 pandemic
    Another influenza season in the shadow of the COVID-19 pandemic
    Sherif Beniameen Mossad, MD, FACP, FIDSA, FAST
    Cleveland Clinic Journal of Medicine November 2021, 88 (11) 594-597; DOI: https://doi.org/10.3949/ccjm.88a.21095

    Flu season is upon us at the ominous milestone of more than 722,000 US deaths from COVID-19.

  • Teriparatide: Label changes and identifying patients for long-term use
    Paul D. Miller, MD, HDSc (HON), E. Michael Lewiecki, MD, Kelly Krohn, MD and Elliott Schwartz, MD
    Cleveland Clinic Journal of Medicine September 2021, 88 (9) 489-493; DOI: https://doi.org/10.3949/ccjm.88a.21011

    The changes leave clinicians with the challenge of identifying appropriate patients.

  • Statin intolerance and new lipid-lowering treatments
    Oltion Mesi, MD, Charlie Lin, MD, Haitham Ahmed, MD, MPH and Leslie S. Cho, MD
    Cleveland Clinic Journal of Medicine July 2021, 88 (7) 381-387; DOI: https://doi.org/10.3949/ccjm.88a.20165

    The benefits and safety of statin therapy are clear, but adverse effects continue to pose diagnostic and therapeutic challenges.

  • What is causing the ‘long-hauler’ phenomenon after COVID-19?
    Leonard H. Sigal, MD, FACP, FACR, MACR
    Cleveland Clinic Journal of Medicine May 2021, 88 (5) 273-278; DOI: https://doi.org/10.3949/ccjm.88a.21009

    We are still early in our understanding of COVID-19 and its many manifestations.

  • Our evolving understanding of primary aldosteronism
    Ali Mehdi, MD, MEd, FACP, Pratibha Rao, MD, MPH and George Thomas, MD
    Cleveland Clinic Journal of Medicine April 2021, 88 (4) 221-227; DOI: https://doi.org/10.3949/ccjm.88a.20166

    Current screening and confirmatory testing lack sensitivity and carry a poor negative predictive value.

  • COVID-19 diagnostic testing and the psychology of precautions fatigue
    Gregory W. Ruhnke, MD, MS, MPH
    Cleveland Clinic Journal of Medicine January 2021, 88 (1) 19-21; DOI: https://doi.org/10.3949/ccjm.88a.20086

    Overuse of special precautions can lead to diminished vigilance.

  • Prostate cancer screening and the role of PSA: A UK perspective
    Prasanna Sooriakumaran, MD, PhD, FRCSUrol, FEBU
    Cleveland Clinic Journal of Medicine January 2021, 88 (1) 14-16; DOI: https://doi.org/10.3949/ccjm.88a.20164

    We advocate PSA screening for all middle-aged men, especially if they have risk factors.

Pages